Clinical Trials Logo

Emphysema clinical trials

View clinical trials related to Emphysema.

Filter by:

NCT ID: NCT00517998 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study

Start date: May 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of the Biologic Lung Volume Reduction System (BLVR) for patients with advanced emphysema refractory to medical therapy.

NCT ID: NCT00515164 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Start date: August 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study it to evaluate the efficacy and safety of the 20 mL BLVR System in patients with advanced upper lobe predominant emphysema.

NCT ID: NCT00475007 Completed - COPD Clinical Trials

Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema

IBV®Valve
Start date: September 2007
Phase: N/A
Study type: Interventional

This trial is for men and women between the ages of 40 and 74 who have a confirmed diagnosis of emphysema. The objective of the trial is to determine the safety and effectiveness of the IBV Valve at redirecting airflow from diseased portions of the lung to healthier areas to achieve improvement in disease-related health status.

NCT ID: NCT00435253 Completed - Pulmonary Emphysema Clinical Trials

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Start date: February 2007
Phase: Phase 2
Study type: Interventional

Evaluate the efficacy and safety of the 10 mL BLVR System in 1 or 2 treatment sessions (8 subsegments, 4 in each lung) in patients with advanced upper lobe predominant emphysema.

NCT ID: NCT00424528 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

Start date: December 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate and compare the efficacy of arformoterol twice a day and tiotropium once a day (dosed sequentially) versus tiotropium once a day alone in subjects with Chronic Obstructive Pulmonary Disease (COPD).

NCT ID: NCT00413205 Completed - Emphysema Clinical Trials

TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)

Start date: January 2007
Phase: Phase 2
Study type: Interventional

This 2 arm study will investigate the efficacy, safety and tolerability of RAR Gamma versus placebo in ex-smokers with moderate or severe emphysema treated with optimal COPD therapy. Following optimization of COPD therapy (up to 6 weeks) patients will be randomized to receive either RAR Gamma (5mg) or placebo once daily using a 2:1 ratio (active:placebo), in addition to their standard therapy. Following the double-blind treatment period, patients will enter a 4-week follow-up period. The anticipated time on study period is 1-2 years, and the target sample size is 100-500 individuals.

NCT ID: NCT00406705 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

The Effect of Breathing Helium-Hyperoxia During Pulmonary Rehabilitation in Patients With COPD

Start date: March 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine whether breathing helium-hyperoxia during exercise in a pulmonary rehabilitation program can improve the exercise tolerance and health related quality of life of patients with Chronic Obstructive Pulmonary Disease (COPD).

NCT ID: NCT00395083 Terminated - COPD Clinical Trials

Bronchitis and Emphysema Advice and Training to Reduce Hospitalization

BREATH
Start date: July 2006
Phase: Phase 2
Study type: Interventional

EXECUTIVE SUMMARY: Purpose: To evaluate the efficacy and cost-effectiveness of a novel intervention incorporating self-management education, an action plan, and case-management to decrease the risk of hospitalizations due to chronic obstructive pulmonary disease (COPD) among veterans with severe COPD. Hypotheses: Primary Hypothesis: Veterans with COPD who receive a self-management program incorporating education sessions, development of an action plan, and case-management will have a decreased risk of COPD hospitalization compared to standardized COPD care. Primary Objective: In an intent-to-treat analysis, determine the efficacy of a comprehensive self-management program for reducing the risk of COPD hospitalization in veterans with severe COPD in comparison to patients receiving standardized COPD care. Secondary Hypotheses: Compared with standardized COPD care, veterans with COPD who receive a comprehensive self-management intervention will have: A) decreased health-related costs resulting from decreased hospitalizations and outpatient utilization, B) decreased hospitalization rates and average length of stay due to both COPD and all-cause admissions, and C) improvement in a set of outcomes including mortality, health-related quality of life, medication adherence, patient satisfaction, disease knowledge, skill acquisition and self-efficacy. Secondary Objectives: To evaluate the healthcare costs, hospitalization days, mortality, adherence, and health outcomes of a comprehensive self-management program compared to standardized COPD care among patients with severe COPD measured by: A)Healthcare-related costs B)Health services use due to COPD and to all causes C)Clinical outcome measures 1. Mortality 2. Health-related quality of life measured by generic and COPD-specific measures 3. Patient satisfaction 4. Medication adherence 5. Disease knowledge, skill acquisition and self-efficacy In the proposed study, 960 veterans with severe COPD hospitalized in the previous year will be randomly assigned to either a comprehensive case management program or standardized COPD care. The comprehensive group will receive an initial, intense education program with development of an action plan, and regular telephone contacts by a case manager in addition to standardized COPD care. Patients allocated to the control arm will receive standardized care that incorporates guideline-based recommendations including influenza vaccination, a short-acting bronchodilator, and either a long-acting bronchodilator or inhaled corticosteroid inhaler. The study will be conducted in 2 phases, a 12-month feasibility study conducted at 6 VA sites followed by the full study in which an additional 8 sites will enroll patients over the next 24 months. As a result, 180 patients will be initially enrolled in the feasibility study over the first year and the remaining 780 patients will be enrolled in the second and third years of the study when the full study is implemented. Subjects will be followed until the completion of the study, for at least one, and up to four years. The primary outcome is time to first COPD hospitalization.

NCT ID: NCT00391612 Active, not recruiting - Emphysema Clinical Trials

EASE Trial: Exhale Airway Stents for Emphysema

EASE
Start date: May 2006
Phase: Phase 3
Study type: Interventional

This is an international clinical research study evaluating the safety and effectiveness of a new procedure called airway bypass. The goal of this research is to see if airway bypass can relieve hyperinflation (overfilling) of the lungs, thereby improving lung function and reducing shortness of breath in patients with severe homogeneous (diffuse) emphysema. "EASE" stands for Exhale Airway Stents for Emphysema.

NCT ID: NCT00373932 Completed - COPD Clinical Trials

Real-Time Support for Exercise Persistence in COPD

Start date: May 2006
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this exploratory study is to determine the feasibility, acceptability, and efficacy of an exercise persistence intervention for patients with chronic obstructive pulmonary disease (COPD) following pulmonary rehabilitation (PR).